ARTICOLI CORRELATI

Bacterial infections and international travel

Having to undertake a trip, whether for business or leisure, it is necessary to gather detailed information about the places one intends to visit, considering the map of countries where the risk of exposure to "traveler's diseases" is highest.

Complications in bipolar disorder

From the clinical point of view, it should be mentioned that sometimes bipolar disorder may be accompanied by some pre-existing conditions that may aggravate an already quite serious condition, with more intense symptoms, for which the applied therapy may yield results of lesser effectiveness. But which ones are the most present?

Is it possible to stop the progressive worsening of Parkinson’s disease?

parkinson

The
Parkinson’s disease
is a degenerative disease of the central nervous system, first described in 1817 by an English physician, James Parkinson. It is characterized by three main symptoms: slowness of movement, rigidity and tremor. The causes are related to degeneration of certain structures in the central nervous system, where dopamine, the main neurotransmitter essential for controlling bodily movements, is produced. Treatment of the disease still relies on drugs that can either supply the deficient dopamine through its precursor, L-DOPA, or stimulate the cells on which this transmitter acts, the dopaminergic cells. Unfortunately, due to the processes of neuro-degeneration, inherent in Parkinson’s disease, these drugs gradually lose their effectiveness over time.

A pioneering program involving an experimental and innovative drug treatment to be applied directly to the brains of people with the disease was published in the latest issue of the Journal of Parkinson’s Disease in February 2019.

The hope: to restore cells damaged in the course of the disease.

The study is based on providing Parkinson’s disease-compromised brains with increased levels of a naturally occurring growth factor, glial cell line-derived neurotrophic factor (GDNF), which has been shown to be able to regenerate the brain cells impaired dopaminergic pathways in individuals with this condition.

Six patients took part in the initial pilot study that mainly evaluated the safety of the treatment approach. Another 35 people then participated in the actual study, which was carried out in a double-blind manner for the duration of nine months: half of the randomly selected subjects received monthly infusions of GDNF, while the other half were treated with placebo infusions.

A specially designed delivery system using robot-assisted neurosurgery was implanted in each subject to carry out the monthly infusions. This delivery system made it possible to deliver high-dose infusions of GDNF every four weeks directly to disease-affected brain areas with pinpoint accuracy through a transcutaneous port mounted on the skull behind the ear. The high compliance rate (99.1%) in participants recruited throughout the United Kingdom demonstrated that the drug delivery system, by repeated cerebral infusion, is feasible and tolerable.

After 18 months of therapy, all of the patients who had received GDNF showed improvement in disease-affected brain areas and related symptoms with a moderate to major rating from the researchers compared with the initial condition. This improvement was also observed in those subjects who were initially placed in the placebo group and then switched to GDNF treatment. GDNF administration proved to be safe throughout the study period.

The study’s principal investigator, Dr. Alan L. Whone of Bristol Medical School at the University of Bristol, UK, stated that: “ In GDNF-treated subjects The improvement in disease-affected areas went beyond what has ever been seen before” and then added that: “High doses of GDNF are able to awaken and restore dopaminergic brain cells, which are progressively impaired in the course of Parkinson’s disease.”.

Even in light of the neurodegenerative process underlying Parkinson’s disease, the drugs currently in use are likely to gradually lose their effectiveness. Therefore, there is no doubt that this study, if confirmed by subsequent evaluations, represents a decisive breakthrough in the treatment of Parkinson’s disease.

Source: Alan L. Whone et al:“Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease” published online in the Journal of Parkinson’s Disease, in advance of Volume 9, Issue 2 (April 2019) by IOS Press

SPECIALISTI IN EVIDENZA

  • Profile picture of Dr. Giuseppe Lepore
    active 3 years, 9 months ago

    Dermatologists, Basic Doctors, General Surgeons

    • 19 Via Manzoni Alessandro - Garbagnate Milanese
    phone
  • Profile picture of Dott.ssa OLGA PETROVSKAIA
    active 3 years, 9 months ago

    Pain therapists, Basic Doctors, Therapist

    • Via Giulio Romano 3 - Valle Martella
    phone
  • Profile picture of Dott. Giovanni Adamo
    active 3 years, 9 months ago

    Angiologists, Basic Doctors

    • Provincia di Ragusa - Ragusa
    phone
  • Profile picture of Dott.ssa Floriana Di Martino
    active 3 years, 9 months ago

    Aesthetic Doctors, Basic Doctors

    • Piazza della Rinascita 13 - Pescara
    phone
  • Profile picture of Dr. Sergio Ettore Salteri
    active 3 years, 9 months ago

    Basic Doctors, Chiropractors, Posturologists

    • Via Vial di Romans 8 - Cordenons
    phone

PATOLOGIE CORRELATE

Borderline personality disorder

Borderline personality disorder is a psychiatric disorder characterized by a fluctuating perception of one’s value and identity, with sudden swings from a very positive and idealized view of oneself to

Bruxism

Bruxism is a condition in which you grind your teeth: it can happen, unconsciously, in a waking state or, more often, during sleep. People who clench or grind their teeth

Parkinson’s disease

Parkinson’s disease is an aging-related neurodegenerative disorder of the central nervous system, affecting about 2.5% of people over 70 years of age, which is mainly characterized by resting tremor in

Uncontrolled eating disorder

Uncontrolled eating disorder is an eating behavior disorder that is characterized by an inability to control food intake, resulting in the more or less frequent repetition of binges similar to

Anxiety

Anxiety or, more precisely, “generalized anxiety disorder,” as stated in the “Statistical Diagnostic Manual of Mental Disorders-DSM 5.” It is a psychiatric illness characterized by: intense and persistent worry and

Bulimia nervosa

Bulimia nervosa is a more widespread eating disorder than is generally believed and widely underdiagnosed, especially in its mild forms, which can go unnoticed unless those affected seek medical/psychiatric help

Obsessive compulsive disorder

Obsessive compulsive disorder is a psychiatric disorder characterized by recurring thoughts, accompanied by completely irrational and unfounded fears and worries, that lead the sufferer to continuously repeat, in an obsessive

Trigeminal neuralgia

The trigeminal nerve is the fifth of the twelve pairs of cranial nerves in the head; it is the nerve responsible for providing sensation to the face. One trigeminal nerve

Morton’s neuroma

Morton’s neuroma consists of a thickening of the tissue surrounding a nerve tract present in the sole of the foot at the anterior (forefoot) support area, usually at the base

Schizophrenia

Schizophrenia is a severe and disabling chronic psychiatric illness that mainly arises in late adolescence or early adulthood, resulting in an altered perception of reality and consequent improper and unpredictable
CULTURA E SALUTE
 
AGGIORNAMENTI
 
PERCORSI
 

your advertising
exclusively ON
MY SPECIAL DOCTOR

complete the form and you will be contacted by one of our managers